Response to aspirin in healthy individuals

Summary

Variable biological effect of aspirin is suggested to be related to pharmacological resistance. The incidence of this so-called “resistant” state varies with the study population and the assay used. We determined performance features of five assays used to assess aspirin effects in non-smoking healthy volunteers not taking any drug known to interfere with platelet function. Blood and urine samples were obtained immediately before and after 8–10 days of aspirin 80 mg intake. Forty-five participants 19–59 years old were enrolled. The sensitivity (SE), specificity (SP), and optimal cut-off (CO) value to detect the effect of aspirin were: light transmission aggregometry (LTA) with 1.6 mM arachidonic acid (AA) – SE 100%,SP 95.9%,CO 20%;LTA with adenosine diphosphate (ADP) 10 µM – SE 84.4%, SP 77.8%, CO 70%; Ver-

Keywords

Agregometry - aspirin - thromboelastography - thromboxane - VerifyNow

^* Institution where work was carried out: Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada

• References

• 1 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
• 2 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
• 3 Gum PA, Kottke-Marchant K, Poggio ED. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
• 4 Pulcinelli FM, Pignatelli P, Celestini A. et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004; 43: 979-984.
• 5 Wang JC, Aucoin-Barry D, Manuelian D. et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003; 92: 1492-1494.
• 6 Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
• 7 Chen WH, Lee PY, Ng W. et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126.
• 8 Becker DM, Segal J, Vaidya D. et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. J Am Med Assoc 2006; 295: 1420-1427.
• 9 Davis JW, Hartman CR, Lewis Jr. HD. et al. Cigarette smoking--induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med 1985; 105: 479-483.
• 10 Hung J, Lam JYT, Lacoste L. et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-2436.
• 11 Gulmez O, Yildirir A, Bal U. et al. Assessment of biochemical aspirin resistance at rest and immediately after exercise testing. Blood Coagul Fibrinolysis 2007; 18: 9-13.
• 12 Watala C, Golanski J, Pluta J. et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)--its relation to metabolic control. Thromb Res 2004; 113: 101-113.
• 13 Friend M, Vucenik I, Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. Br Med J 2003; 326: 82-83.
• 14 Szczeklik A, Musial J, Undas A. et al. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 948-954.
• 15 Zimmermann N, Wenk A, Kim U. et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-547.
• 16 Fontana P, Nolli S, Reber G. et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006; 04: 813-819.
• 17 Frelinger AL, Li Y, Linden MD. et al. Aspirin ‘resistance’: role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 06: 2035-2044.
• 18 Madsen EH, Schmidt EB, Maurer-Spurej E. et al. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 2008; 19: 335-341.
• 19 Faraday N, Becker DM, Yanek LR. et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006; 98: 774-779.
• 20 Feher G, Feher A, Pusch G. et al. The genetics of antiplatelet drug resistance. Clin Genet 2009; 75: 1-18.
• 21 Burke J, Kraft WK, Greenberg HE. et al. Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation. J Clin Pharmacol 2003; 43: 983-989.
• 22 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
• 23 Lordkipanidze M, Pharand C, Schampaert E. et al. Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry. Thromb Res. 2009 epub ahead of print..
• 24 Harrison P. Advances in platelet counting. Br J Haematol 2000; 111: 733-744.
• 25 Nicholson N, Panzer-Knodle S, Haas N. et al. Assessment of platelet function assays. Am Heart J 1998; 135: S170-S178.
• 26 Bochsen L, Wiinberg B, Kjelgaard-Hansen M. et al. Evaluation of the TEG platelet mapping assay in blood donors. Thromb J 2007; 05: 3.
• 27 Rivard G, Cohen E, Hofer A. et al. The use of thrombelastograph to monitor the aspirin induced inhibition of platelet response to arachidonic acid. Blood 2003; 102: 65b.
• 28 Catella F, Healy D, Lawson JA. et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861-5865.
• 29 Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218.
• 30 Solberg H. The theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1987; 25: 645-656.
• 31 NCCLS. How to Define and Determine Reference Intervals in the Clinical Laboratory; Approved Guideline---Second Edition. NCCLS document C28-A2. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA. 2000
• 32 Lordkipanidze M, Pharand C, Schampaert E. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
• 33 Dyszkiewicz-Korpanty AM, Kim A, Burner JD. et al. Comparison of a rapid platelet function assay - Verify Nowtrade mark Aspirin - with whole blood impedance aggregometry for the detection of aspirin resistance. Thromb Res 2007; 120: 485-488.
• 34 Santos MT, Valles J, Lago A. et al. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 2008; 06: 615-621.
• 35 Lennon MJ, Gibbs NM, Weightman WM. et al. A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004; 18: 136-140.
• 36 Dichiara J, Bliden KP, Tantry US. et al. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 2007; 18: 414-423.
• 37 Helena Laboratories. Point Of Care. Helena Plateletworks. Plateletworks Arachidonic Acid Procedure, Pro 119 Rev 3. Available at: http://www.helena.com/ Procedures/Pro119Rev3.pdf Accessed March 21,2009
• 38 Mayne E, Jacobson B, Louw S. et al. The utility of thrombo-elastography in the monitoring of aspirin therapy. S Afr Med J 2007; 97: 1289-1291.
• 39 Hobson AR, Petley GW, Dawkins KD. et al. A novel fifteen minute test for assessment of individual timedependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets 2007; 18: 497-505.
• 40 Berger JS, Roncaglioni MC, Avanzini F. et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. J Am Med Assoc 2006; 295: 306-313.
• 41 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
• 42 Reny JL, de Moerloose P, Dauzat M. et al. Use of the PFA-100trade mark closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 06: 444-450.
• 43 Guthikonda S, Mangalpally K, Vaduganathan M. et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost 2008; 100: 83-89.
• 44 Gori AM, Marcucci R, Paniccia R. et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008; 100: 1136-1145.